(Q36852683)

16 August 2017

1 reference

title

A review of combination therapy in patients with benign prostatic hyperplasia (English)

1 reference

16 August 2017

Kevin T McVary

1

1 reference

16 August 2017

publication date

1 March 2007

1 reference

16 August 2017

published in

Clinical Therapeutics

1 reference

16 August 2017

volume

29

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

387-398

1 reference

UROLOGIC DISEASES IN AMERICA PROJECT: BENIGN PROSTATIC HYPERPLASIA

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Light Microscopic Stereological Analysis of the Normal Human Prostate and of Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Etiology and disease process of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

The development of human benign prostatic hyperplasia with age

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2807%2980077-4

7 January 2021

10.1016/S0149-2918(07)80077-4

Identifiers

DOI

1 reference

16 August 2017

1 reference